Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms

Abstract

Androgen deprivation therapy targeting the androgens/androgen receptor (AR) signaling continues to be the mainstay treatment of advanced-stage prostate cancer. The use of second-generation antiandrogens, such as abiraterone acetate and enzalutamide, has improved the survival of prostate cancer patients; however, a majority of these patients progress to castration-resistant prostate cancer (CRPC). The mechanisms of resistance to antiandrogen treatments are complex, including specific mutations, alternative splicing, and amplification of oncogenic proteins resulting in dysregulation of various signaling pathways. In this review, we focus on the major mechanisms of acquired resistance to second generation antiandrogens, including AR-dependent and AR-independent resistance mechanisms as well as other resistance mechanisms leading to CRPC emergence. Evolving knowledge of resistance mechanisms to AR targeted treatments will lead to additional research on designing more effective therapies for advanced-stage prostate cancer.

Keywords

Prostate cancer / second-generation antiandrogens / androgen receptor / castration resistance prostate cancer

References

[1] Leslie SW,Sajjad H.Prostate cancer. StatPearls [Internet].2019;Treasure Island (FL)StatPearls Publishing

[2] American Cancer SocietyCancer facts and figures 2020.2020;AtlantaAmerican Cancer Society

[3] Gamat M.Androgen deprivation and immunotherapy for the treatment of prostate cancer..Endocr Relat Cancer2017;24:297-310 PMCID:PMC5669826

[4] Kita Y,Akamatsu S,Inoue T.Castration-resistant prostate cancer refractory to second-generation androgen receptor axis-targeted agents: opportunities and challenges..Cancers2018;10:345-60 PMCID:PMC6210307

[5] Feng Q.Androgen receptor signaling in the development of castration- resistant prostate cancer..Front Oncol2019;9:179-97

[6] Linder S,Bergman AM,Prekovic S.Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond..Endocr Relat Cancer2019;26:31-52 PMCID:PMC6215909

[7] Tan ME,Xu HE,Yong EL.Androgen receptor: structure, role in prostate cancer and drug discovery..Acta Pharmacologica Sinica2015;36:3-23 PMCID:PMC4571323

[8] Jin Y,Wang X,Zhou W.Communication between the ligand-binding pocket and the activation function-2 domain of androgen receptor revealed by molecular dynamics simulations..J Chem Inf Model2019;59:842-57

[9] Itkonen H.Chromatin binding by the androgen receptor in prostate cancer..Mol Cell Endocrinol2012;360:44-51

[10] Mills IG.Maintaining and reprogramming genomic androgen receptor activity in prostate cancer..Nat Rev Cancer2014;14:187-98

[11] Chen CD,Tran C,Chen R.Molecular determinants of resistance to antiandrogen therapy..Nat Med2004;10:33-9

[12] Robinson D,Wu YM,Lonigro RJ.Integrative clinical genomics of advanced prostate cancer..Cell2015;161:1215-28 PMCID:PMC4484602

[13] Takeda DY,Seo JH,O’Connor E.A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer..Cell2018;174:422-32 PMCID:PMC6046260

[14] Quigley DA,Zhao SG,Aggarwal R.Genomic hallmarks and structural variation in metastatic prostate cancer..Cell2018;174:758-69 PMCID:PMC6425931

[15] Gomella LG.Effective testosterone suppression for prostate cancer: is there a best castration therapy?.Rev Urol2009;11:52-60 PMCID:PMC2725306

[16] Crona DJ.Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance..Cancers2017;9:1-18

[17] Gauthier S,Labrie F.Steroid derivatives as pure antagonists of the androgen receptor..J Steroid Biochem. Mol Biol2012;132:93-104

[18] Liu VW,Tam CW,Shiu SY.Melatonin inhibits androgen receptor splice variant-7 (AR-V7)-induced nuclear factor-kappa B (NF-κB) activation and NF-κB activator-induced AR-V7 expression in prostate cancer cells: potential implications for the use of melatonin in castration-resistant prostate cancer (CRPC) therapy..Int J Mol Sci2017;18:1-13 PMCID:PMC5485954

[19] Vasaitis TS,Njar VC.CYP17 inhibitors for prostate cancer therapy..J Steroid Biochem Mol Biol2011;125:23-31 PMCID:PMC3047603

[20] Potter GA,Jarman M.Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-c17,20-lyase): potential agents for the treatment of prostatic cancer..J Med Chem1995;38:2463-71

[21] Porubek D.CYP17A1: a biochemistry, chemistry, and clinical review,.Curr Top Med Chem2013;13:1364-84

[22] Attard G,Olmos D.Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven..Cancer Res2009;69:4937-40

[23] Sternberg CN,Madan RA.Progress in the treatment of advanced prostate cancer..Am Soc Clin Oncol Educ Book2014;34:117-31

[24] Cai C,Ng P,Nelson PS.Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors..Cancer Res2011;71:6503-13 PMCID:PMC3209585

[25] Chang KH,Kuri B,Roehrborn CG.A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer..Cell2013;154:1074-84 PMCID:PMC3931012

[26] de Bono JS,Molina A,North S.Abiraterone and increased survival in metastatic prostate cancer..N Engl J Med2011;364:1995-2005 PMCID:PMC3471149

[27] Ryan CJ,de Bono JS,Logothetis CJ.Abiraterone in metastatic prostate cancer without previous chemotherapy..N Engl J Med2013;368:138-48 PMCID:PMC3683570

[28] Scher HI,Saad F,Sternberg CN.Increased survival with enzalutamide in prostate cancer after chemotherapy..New Engl Journal Med2012;367:1187-97

[29] Beer TM,Rathkopf DE,Sternberg CN.Enzalutamide in metastatic prostate cancer before chemotherapy..New Engl J Med2014;371:424-33 PMCID:PMC4418931

[30] Antonarakis ES,Wang H,Nakazawa M.AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer..New Engl J Med2014;371:1028-18 PMCID:PMC4201502

[31] Mostaghel EA,Montgomery B.Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit..Clin Cancer Res2014;20:791-8 PMCID:PMC3944407

[32] Coutinho I,Tilley WD.Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence..Endocr Relat Cancer2016;23:179-97

[33] Tucci M,Buttigliero C,Scagliotti GV.Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions..Onco Targets Ther2018;11:7353-68 PMCID:PMC6204864

[34] Bohl CE,Miller DD,Dalton JT.Structural basis for antagonism and resistance of bicalutamide in prostate cancer..Proc Natl Acad Sci U S A2005;102:6201-6 PMCID:PMC1087923

[35] Buchanan G,Cheong A,Irvine RA.Structural and functional consequences of glutamine tract variation in the androgen receptor..Human molecular genetics.2004;13:1677-92

[36] Giovannucci E,Krithivas K,Dahl D.The CAG repeat within the androgen receptor gene and its relationship to prostate cancer..Proc Natl Acad Sci USA1997;94:3320-3 PMCID:PMC20367

[37] Hsing AW,Wu G,Deng J.Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China..Cancer Res2000;60:5111-6

[38] Stanford JL,Gibbs M,Neal CL.Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk..Cancer Res1997;57:1194-8

[39] Beilin J,Favaloro JM.Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines..J Mol Endocrinol2000;25:85-96

[40] Brooke GN.The role of androgen receptor mutations in prostate cancer progression..Curr Genomics2009;10:18-25 PMCID:PMC2699836

[41] Golias C,Peschos D.Amplification and co-regulators of androgen receptor gene in prostate cancer..Exp Oncol2009;31:3-8

[42] Nakazawa M,Luo J.Androgen receptor splices variants in the era of enzalutamide and abiraterone..Horm Cancer2014;5:265-73 PMCID:PMC4167475

[43] Guo Z,Sun F,Linn DE.A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth..Cancer Res2009;69:2305-13 PMCID:PMC2672822

[44] Hu R,Wei S,Veltri RW.Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer..Cancer Res2009;69:16-22 PMCID:PMC2614301

[45] Chen X,Tolkach Y,Nientiedt C.Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy..Urol Oncol2018;36:161.e19-30

[46] Sun S,Vessella RL,Soriano K.Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant..J Clin Invest2010;120:2715-30 PMCID:PMC2912187

[47] Liu T,Gu H,Li J.p21-Activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2)..J Biol Chem2013;288:3359-69 PMCID:PMC3561555

[48] Zhang X,Sun S,Nelson PS.Androgen receptor variants occur frequently in castration resistant prostate cancer metastases..PLoS One2011;6:1-11 PMCID:PMC3219707

[49] Tagawa ST,Gjyrezi A,Kim S.Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY..Clin Cancer Res2019;25:1880-8 PMCID:PMC6432911

[50] Payton S.Prostate cancer: new insight into mechanisms of castration resistance..Nat Rev Urol2010;7:590

[51] Huang Y,Liang X.Molecular and cellular mechanisms of castration resistant prostate cancer..Oncol lett2018;15:6063-76 PMCID:PMC5876469

[52] Zhan Y,Wang X,Bai S.Interplay between cytoplasmic and nuclear androgen receptor splice variants mediates castration resistance..Mol Cancer Res2017;15:59-68 PMCID:PMC5215946

[53] Yang X,Sun F,Alfano A.Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells..J Biol Chem2011;286:36152-60 PMCID:PMC3195613

[54] Stanbrough M,Ross K,Rubin MA.Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer..Cancer Res2006;66:2815-25

[55] Khan OY,Ismail A,Cao X.Multifunction steroid receptor coactivator, E6-associated protein, is involved in development of the prostate gland..Mol Endocrinol2006;20:544-59

[56] Beitel LK,Lumbroso R,Panet-Raymond V.Cloning and characterization of an androgen receptor N-terminal-interacting protein with ubiquitin-protein ligase activity..J Mol Endocrinol2002;29:2941-60

[57] He B,Hnat AT,Minges JT.An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP)..J Biol Chem2004;279:30643-53

[58] Moilanen AM,Karvonen U,Janne OA.Identification of a novel RING finger protein as a coregulator in steroid receptor-mediated gene transcription..Mol Cell Biol1998;18:5128-39 PMCID:PMC109098

[59] Xu K,Linn DE,Yang X.Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination..Cancer Cell2009;15:270-82 PMCID:PMC2848969

[60] Qi J,Mishra R,Fazli L.The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity..Cancer Cell2013;23:332-46 PMCID:PMC3750989

[61] Jing Y,Wang D,Guo W.DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor..Oncogene2018;37:6380-650 PMCID:PMC5794523

[62] Kirmizibayrak PB,Gozen O.Divergent modulation of proteostasis in prostate cancer..Adv Exp Med Biol2020;1233:117-51

[63] Meric-Bernstam F,Chen HQ,Sangai T.PIK3CA/PTEN mutations and akt activation as markers of sensitivity to allosteric mTOR inhibitors..Clin Cancer Res2012;18:1777-89 PMCID:PMC3307149

[64] Taylor BS,Hieronymus H,Xiao Y.Integrative genomic profiling of human prostate cancer..Cancer Cell2010;18:11-22 PMCID:PMC3198787

[65] Carver BS,Wongvipat J,Chen Y.Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer..Cancer Cell2011;19:575-86 PMCID:PMC3142785

[66] Pourmand G,Abedi AR,Alavi HA.Role of PTEN gene in progression of prostate cancer..Urol J2007;4:95-100

[67] de Bono JS,Massard C,Nava Rodrigues D.PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)..Ann Oncol2016;27:243-65

[68] Toren P.Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities..Int J Oncol2014;45:1793-801

[69] Fruman DA,Hopkins BD,Cantley LC.The PI3K pathway in human disease..Cell2017;170:605-35 PMCID:PMC5726441

[70] Li B,Jiang W,Terranova P.PI-3 kinase p110β: a therapeutic target in advanced prostate cancers..Am J Clin Exp Urol2014;2:188-98 PMCID:PMC4219313

[71] Leung JK.Non-genomic actions of the androgen receptor in prostate cancer..Front endocrinol2017;8:1-8 PMCID:PMC5239799

[72] Chandrasekar T,Gao AC.Mechanisms of resistance in castration-resistant prostate cancer (CRPC)..Transl Androl Urol2015;4:365-80 PMCID:PMC4708226

[73] Thomas C,Crafter C,Beraldi E.Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castrationresistant prostate cancer progression in vivo..Mol Cancer Ther2013;12:2342-55

[74] Kino T. Glucocorticoid receptor. In: De Groot LJ, Chrousos G, Dungan K, et al, editors. Endotext [Internet]. South Dartmouth: MDText.com, Inc.; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279171/. [last accessed on 14 Sep 2020]

[75] Davey RA.Androgen receptor structure, function and biology: from bench to bedside..Clin Biochem Rev2016;37:3-15 PMCID:PMC4810760

[76] Scheschowitsch K,Assreuy J.New insights in glucocorticoid receptor signaling-more than just a ligand binding receptor..Front endocrinol2017;8:1-9 PMCID:PMC5292432

[77] Venkitaraman R,Huddart RA,Dearnaley DP.Efficacy of low-dose dexamethasone in castration-refractory prostate cancer..BJU Int2008;101:440-3

[78] Yemelyanov A,Chebotaev D,Kulevitch E.Tumor suppressor activity of glucocorticoid receptor in the prostate..Oncogenoe2007;26:1885-96

[79] Arora VK,Murali R,Wongvipat J.Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade..Cell2013;155:1309-22 PMCID:PMC3932525

[80] Isikbay M,Kregel S,Cai Y.Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer..Horm Cancer2014;5:72-89 PMCID:PMC4440041

[81] Puhr M,Eigentler A,Handle F.The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved antiandrogen therapy..Clin Cancer Res2018;24:927-38

[82] Li J,Zhang A,Berk M.Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer..Elife2017;6:1-17 PMCID:PMC5305204

[83] Xia Y,Verma IM.NF-κB, an active player in human cancers..Cancer Immunol Res2014;2:823-30 PMCID:PMC4155602

[84] Ghosh S.Missing pieces in the NF-κB puzzle..Cell2002;109:81-96

[85] Zhang L,Deng F,Lal P.NF-κB regulates androgen receptor expression and prostate cancer growth..Am J Pathol2009;175:489-99 PMCID:PMC2716950

[86] Cui Y,Liu C,Schwartz CT.Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells..Endocr Relat Cancer2014;21:435-42 PMCID:PMC4021715

[87] Nadiminty N,Sun M,Yue J.Aberrant activation of the androgen receptor by NF-κB2/p52 in prostate cancer cells..Cancer Res2010;70:3309-19 PMCID:PMC3041633

[88] Shilo A,Karni R.The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression..Mol Cell Oncol2015;2:1-14 PMCID:PMC4905244

[89] Nadiminty N,Liu C,Lou W.NF-kappaB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants..Mol Cancer Ther2013;12:1629-37 PMCID:PMC3941973

[90] Jin R,Yu X,Franco OE.Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression..Oncogene2015;34:3700-10 PMCID:PMC4362792

[91] Culig Z.Molecular mechanisms of enzalutamide resistance in prostate cancer..Curr Mol Biol Rep2017;3:230-5 PMCID:PMC5700216

[92] Azevedo A,Teixeira AL.IL-6/IL-6R as a potential key signaling pathway in prostate cancer development..World J Clin Oncol2011;2:384-96 PMCID:PMC3235657

[93] Johnson DE,Grandis JR.Targeting the IL-6/JAK/STAT3 signalling axis in cancer..Nat Rev Clin Oncol2018;15:234-48 PMCID:PMC5858971

[94] Liu C,Lou W,Evans CP.Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells..Prostate2014;74:201-9 PMCID:PMC4437226

[95] Datta SR,Tao X,Fu H.Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery..Cell1997;91:231-41

[96] Cardone MH,Stennicke HR,Franke TF.Regulation of cell death protease caspase-9 by phosphorylation..Science1998;282:1318-21

[97] Biggs WH,Hunter T,Arden KC.Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1..Proc Natl Acad Sci U S A1999;96:7421-6 PMCID:PMC22101

[98] Baron S,Beaudoin C,Communal Y.Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells..J Biol Chem2004;279:14579-86

[99] Nakae J,Accili D.Differential regulation of gene expression by insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR..EMBO J2000;19:989-96 PMCID:PMC305638

[100] Zhao Y,Huang H.Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer..Int J Biol Sci2014;10:614-9 PMCID:PMC4062954

[101] Liu P,Gan L,Huang H.A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells..Cancer Res2008;68:10290-9

[102] Das TP,Alatassi H,Damodaran C.Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer..Cell Death Dis2016;7:1-10 PMCID:PMC4849149

[103] Ketola K,Davies A,Bishop JL.Targeting prostate cancer subtype 1 by forkhead box M1 pathway inhibition..Clin Cancer Res2017;23:6923-33

[104] Zhang X,Huang YT,Zhou HH.Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma..J Exp Clin Cancer Res2017;36:1-18 PMCID:PMC5547476

[105] Puigserver P,Donovan J,Yoon JC.Nature2003;423:550-5

[106] Schneider JA.Revisiting the role of Wnt/β-catenin signaling in prostate cancer..Mol Cell Endocrinol2018;462:3-8 PMCID:PMC5550366

[107] Clevers H.Wnt/β-catenin signaling and disease..Cell2012;149:1192-205

[108] Wang G,Sadar MD.Crosstalk between the androgen receptor and beta catenin in castrate-resistant prostate cancer..Cancer Res2008;68:9918-27 PMCID:PMC2654418

[109] Rajan P,Villasevil MEM,Fleming J.Next-generation sequencing of advanced prostate cancer treated with androgen deprivation therapy..European Urol2014;66:32-9 PMCID:PMC4062940

[110] Yokoyama NN,Hoang BH,Zi X.Wnt signaling in castration-resistant prostate cancer: implications for therapy..Am J Clin Exp Urol2014;2:27-44 PMCID:PMC4219296

[111] Li ZG,Vazquez ES,Vakar-Lopez F.Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone..Oncogene2008;27:596-603

[112] Sun Y,Higano C,Porter P.Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B..Nat Med2012;18:1359-68 PMCID:PMC3677971

[113] Patriarca C,Campo B,Giunta P.Elevated E-cadherin and alpha/beta-catenin expression after androgen deprivation therapy in prostate adenocarcinoma..Pathol Res Pr2003;199:659-65

[114] Beltran H,Frampton GM,Downing SR.Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity..Eur Urol2013;63:920-6 PMCID:PMC3615043

[115] Grasso CS,Robinson DR,Dhanasekaran SM.The mutational landscape of lethal castration-resistant prostate cancer..Nature2012;487:239-43 PMCID:PMC3396711

[116] Velho PI,Wang H,Qazi F.Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer..Eur Urol2020;77:14-21 PMCID:PMC6893106

[117] Chesire DR,Gage WR.In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis..Oncogene2002;21:2679-94

[118] De la Taille A,Chen MW,de Medina SGD.Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells..Clin Cancer Res2003;9:1801-7

[119] Chen X,Cheng L,Zhang Z.Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer..Prostate2020;80:256-66

[120] Zhang Z,Li J,Atallah NM.Inhibition of the Wnt/β-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate cancer..Cancer Res2018;78:3147-62 PMCID:PMC6004251

[121] Culig Z.Proinflammatory cytokine interleukin-6 in prostate carcinogenesis..Am J Clin Exp Urol2014;2:231-8 PMCID:PMC4219316

[122] Culig Z.Interleukin-6 and prostate cancer: Current developments and unsolved questions..Mol Cell Endocrinol2018;462:25-30

[123] Luo M,Song Y,Zhou R.Nuclear autophagy: an evolutionarily conserved mechanism of nuclear degradation in the cytoplasm..Autophagy2016;12:1973-83 PMCID:PMC5103339

[124] Glick D,Macleod KF.Autophagy: cellular and molecular mechanisms..J Pathol2010;221:3-12 PMCID:PMC2990190

[125] Gump JM.Autophagy and apoptosis: what is the connection?.Trends Cell Biol2011;21:387-92 PMCID:PMC3539742

[126] Farrow JM,Evans CP.Autophagy as a modulator and target in prostate cancer..Nat Rev Urol2014;11:508-16 PMCID:PMC4415606

[127] Nguyen HG,Kung HJ,Tilki D.Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model..Oncogene2014;33:4521-30 PMCID:PMC4155805

[128] Matsumoto H,Shiota M,Beraldi E.Cotargeting androgen receptor and clusterin delays castrate-resistant prostate cancer progression by inhibiting adaptive stress response and AR stability..Cancer Res2013;73:5206-17

[129] Montanari M,Cavaliere C,Malzone MG.Epithelial-mesenchymal transition in prostate cancer: an overview..Oncotarget2017;8:35376-89 PMCID:PMC5471062

[130] Shiota M,Takeuchi A,Kashiwagi E.Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer..Clin Cancer Res2014;20:951-61

[131] Ware KE,Schaeffer D,Zhang T.Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer..Oncotarget2016;7:50507-21 PMCID:PMC5226599

[132] Conteduca V,Eng KW,Sigouros M.Clinical features of neuroendocrine prostate cancer..Eur J Cancer2019;121:7-18 PMCID:PMC6803064

[133] Lee GT,Kim WT,Palapattu G.TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer..PLoS One2019;14:1-18 PMCID:PMC6752758

[134] Carver BS.Defining and targeting the oncogenic drivers of neuroendocrine prostate cancer..Cancer cell2016;29:431-2 PMCID:PMC5550814

[135] Mosquera JM,Park K,Robinson BD.Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer..Neoplasia (New York, NY)2013;15:1-10 PMCID:PMC3556934

[136] Dardenne E,Benelli M,Berger A.N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer..Cancer cell2016;30:563-77 PMCID:PMC5540451

[137] Lee JK,Smith BA,Stoyanova T.N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells..Cancer Cell2016;29:536-47 PMCID:PMC4829466

[138] Guo H,Ahmed M,Soares F.ONECUT2 is a driver of neuroendocrine prostate cancer..Nat Commun2019;10:278 PMCID:PMC6336817

[139] Kaochar S.Multimodal action of ONECUT2 in driving neuroendocrine prostate cancer..Transl Cancer Res2019;8:1-6 PMCID:PMC6662936

[140] Chen R,Gleave M.Molecular model for neuroendocrine prostate cancer progression..BJU Int2018;122:560-70

[141] Mu P,Benelli M,Hoover E.SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer..Science2017;3556320:84-88 PMCID:PMC5247742

[142] Tan HL,Rahimi HA,Gupta N.Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma..Clin Cancer Res2014;20:890-903 PMCID:PMC3931005

[143] Gupta K.Neuroendocrine differentiation in prostate cancer: key epigenetic players..Transl Cancer Res2017;6:104-8 PMCID:PMC6320222

[144] Ku SY,Wang Y,Seshadri M.Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance..Science2017;355:78-83 PMCID:PMC5367887

[145] Bishop JL,Angeles A,Azad AA.PD-L1 is highly expressed in Enzalutamide resistant prostate cancer..Oncotarget2015;6:234-42 PMCID:PMC4381591

[146] Rickman DS,Banerjee S,Yu J.ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression..Neoplasia2010;12:1031-40 PMCID:PMC3003138

[147] Gerke JS,Tolkach Y,Wehweck FS.Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma..Int J Cancer2020;146:2036-46

[148] Huret JL,Arsaban M,Cigna J.Atlas of genetics and cytogenetics in oncology and haematology in 2013..Nucleic Acids Res2012;41:920-4 PMCID:PMC3531131

[149] Tomlins SA,Perner S,Mehra R.Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer..Science2005;310:644-8

[150] Shore N,Saad F.Predicting response and recognizing resistance: improving outcomes in patients with castration-resistant prostate cancer..Urology2017;109:6-18

[151] Attard G,Yap TA,Dowsett M.Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostrate cancer commonly remains hor-mone driven..J Clin Oncol2008;26:4563-71